Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval

November 21, 2017 – The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non–small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation. The agency is reviewing data from the phase III PACIFIC trial, the results of which have now been published in the print edition of the New England Journal Medicine. In the study, durvalumab improved progression-free … (leggi tutto)